International journal of clinical and experimental pathology最新文献

{"title":"Primary thyroid lymphoma -- report of four cases and literature review.","authors":"Haoying Sun,&nbsp;Jinzhu Ma,&nbsp;Yibo Chen,&nbsp;Ming Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to investigate the pathogenesis, clinical characteristics, diagnosis, treatment, and prognosis of primary thyroid lymphoma (PTL) for a better understanding of the disease and a more accurate PTL diagnosis, thereby preventing misdiagnosis and mistreatment.</p><p><strong>Methods: </strong>The clinical manifestations, biochemical examination, ultrasound examination, imaging examination, pathologic examination, diagnosis, and treatment of four PLT patients admitted to the Department of Thyroid and Breast Surgery of the Affiliated Hospital of Inner Mongolia Medical University from January 2010 to December 2020 were retrospectively analyzed.</p><p><strong>Results: </strong>Diffuse large B-cell lymphoma (DLBCL) expressing cluster of differentiation 20 (CD20) were detected in all four PTL patients. Hashimoto's thyroiditis (HT) with increased anti-thyroglobulin antibodies (TGAb) occurred in two PTL patients, while antithyroid peroxidase autoantibody (TPOAb) was increased in three cases. All four patients underwent surgical and chemoradiotherapy treatments. Patients were without tumors during the follow-up ranging from 8 to 55 months.</p><p><strong>Conclusion: </strong>PTL is a primary extranodal lymphoma of the thyroid and is mainly derived from B-cell non-Hodgkin's lymphoma. The pathogenesis of PTL remains unclear, but it is closely related to HT. Clinical diagnosis in this study was determined by either needle biopsy or surgical resection.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 5","pages":"99-107"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244227/pdf/ijcep0016-0099.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9663297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: influencing factors and prognostic significance.","authors":"Xingang Lu,&nbsp;Ruihua Qi,&nbsp;Ying Xu,&nbsp;Xiao Wang,&nbsp;Yibo Cai,&nbsp;Chunliang Wang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>The extent of tumor regression varies widely among patients who receive neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision (TME) surgery. We evaluated the tumor regression grade (TRG) classification of patients and analyzed factors related to TRG and its value in predicting prognosis in locally advanced rectal cancer (LARC).</p><p><strong>Methods: </strong>This study retrospectively analyzed the clinicopathologic data of 269 consecutive patients with LARC treated from February 2002 to October 2014. The grade of TRG was based on the extent of primary tumor replaced by fibrosis. Clinical characteristics and relative survival were retrospectively analyzed.</p><p><strong>Results: </strong>There were 269 patients, among whom 67 patients (24.9%) achieved TRG0, whereas 46 patients (17.1%) showed TRG3. TRG1 and TRG2 were both found in 78 patients (29.0%). Clinicopathologic factors that were related to TRG included post-NACRT carcinoembryonic antigen (CEA) level (P=0.002), clinical T stage (P=0.022), pathologic T stage (P<0.001) and pathologic lymph node status (P=0.003). The 5-year overall survival (OS) was 74.6%, 55.1%, 47.4%, 28.3% for TRG0, TRG1, TRG2, TRG3, respectively (P<0.001). The 5-year disease-free survival (DFS) was 64.2%, 47.4%, 37.2%, 23.9% for TRG0, TRG1, TRG2, TRG3, respectively (P<0.001). Based on multivariate analysis, TRG was a significant predictor for both OS (P=0.039) and DFS (P=0.043).</p><p><strong>Conclusion: </strong>Clinicopathologic factors such as post-NACRT CEA level, clinical T stage, pathological T stage and pathological lymph node status are significantly associated with TRG. TRG is an independent predictor of survival. Therefore, it is reasonable to include the TRG for clinicopathologic assessment.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 6","pages":"124-132"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326522/pdf/ijcep0016-0124.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9865216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of TLE1 and BCOR as immunohistochemical markers for angiomatoid fibrous histiocytoma.","authors":"Hui Pan,&nbsp;Joshua Byers,&nbsp;Hong Yin,&nbsp;Heather Rytting,&nbsp;Suzanna Logan,&nbsp;Mai He,&nbsp;Zhongxin Yu,&nbsp;Dehua Wang,&nbsp;Shamlal Mangray,&nbsp;Shengmei Zhou","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Diagnosis of angiomatoid fibrous histiocytoma (AFH) can be challenging due to its variable histologic features and a lack of highly sensitive and/or specific immunohistochemical markers. The utility of TLE1 and BCOR as immunohistochemical markers for AFH is not known.</p><p><strong>Methods: </strong>We examined the spectrum of histologic features of 36 AFHs, and studied the expression of both TLE1 and BCOR in AFH and its mimics by immunohistochemical staining. Positive nuclear expression was scored semiquantitatively.</p><p><strong>Results: </strong>Both typical and unusual histologic features of AFHs were observed in this cohort. TLE1 was moderately to strongly positive in 36/36 AFHs, 4/4 synovial sarcomas, and 2/3 BCOR sarcomas; weakly positive in 4/6 inflammatory myofibroblastic tumors; negative in all dermatofibromas (n = 10), atypical fibrous histiocytomas (n = 5), myofibroma (n = 2) and juvenile xanthogranulomas (n = 5), with an overall sensitivity of 100%, and specificity of 71.4% for AFH. BCOR was moderately to strongly positive in 24/36 AFHs, 4/4 synovial sarcomas, 3/3 BCOR sarcomas, and 1/5 atypical fibrous histiocytomas; weakly positive in 10/36 AFHs; negative in the remaining tumors. The overall sensitivity and specificity of BCOR for AFH were 94.4% and 77.1%, respectively.</p><p><strong>Conclusions: </strong>TLE1 is a highly sensitive immunohistochemical marker for AFH.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 2","pages":"32-39"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993016/pdf/ijcep0016-0032.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9109692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive diagnosis and treatment of ductal carcinoma of the submandibular gland: case report and literature review.","authors":"Feng Liu,&nbsp;Li Fan,&nbsp;Lifang Lu,&nbsp;Hongyi Guo,&nbsp;Jie Nan,&nbsp;Fei Han","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Salivary duct carcinoma (SDC) is a rare malignant tumor of the salivary gland and is most commonly found in the parotid gland, followed by the submandibular gland. Due to its rarity, there is no consensus on its treatment. Surgical resection is currently the only curative treatment. Considering its high degree of malignancy, extensive tumor resection and postoperative adjuvant radiotherapy are recommended. We report a rare case of SDC of the submandibular gland. A 62-year-old man presented to our hospital with complaints of swelling in the right submaxillary area for 4 months, rapidly growing, with pain for 10 days. After admission, fine needle aspiration (FNA) revealed right submandibular gland ductal carcinoma. Considering its aggressiveness, large size, and invasion of parapharyngeal and oral floor soft tissues, the patient received two cycles of neoadjuvant chemotherapy followed by extended surgical resection. Postoperatively, the patient received four cycles of concurrent chemoradiotherapy, followed by afatinib targeted therapy. No recurrence or metastasis was observed in a 45-month follow-up. Thus we present a comprehensive treatment for salivary duct carcinoma combining neoadjuvant chemotherapy with surgery, postoperative concurrent radiotherapy, and chemotherapy followed by afatinib targeted therapy.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 3","pages":"67-75"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076972/pdf/ijcep0016-0067.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APOBEC3B expression has prognostic significance in cervical cancer.","authors":"Si-Qi Zhang,&nbsp;Jun Zhang,&nbsp;Yang Yu,&nbsp;Miao-Mei Yu,&nbsp;Jiang Wei,&nbsp;Yan-Hong Tang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Cervical cancer is one of the leading fatal diseases in women, and the role of Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in cervical cancer is uncertain.</p><p><strong>Methods: </strong>Four Gene Expression Omnibus (GEO) mRNA microarray datasets were analyzed to identify differentially expressed genes (DEGs) between cervical cancer and normal cervical tissues. The results were validated using a The Cancer Genome Atlas (TCGA)-cervical cancer (CESC) dataset. Expression profiles and patients' clinical data were used to investigate the relationship between APOBEC3B expression and cervical cancer survival. APOBEC3B co-expressed genes were subjected to enrichment analyses, and correlations between APOBEC3B expression and immunologic infiltrates were investigated using Tumor Immune Estimation Resource (TIMER). We generated receiver operating characteristic curve (ROC) curves to evaluate the performance of APOBEC3B expression in predicting cervical cancer prognosis.</p><p><strong>Results: </strong>Fourteen overlapping DEGs were obtained, and APOBEC3B was chosen as a candidate gene. TCGA data further confirmed that APOBEC3B was significantly increased in cervical cancer, relative to normal adjacent tissues, and this expression was associated with poor clinical outcome. Results from quantitative real time polymerase chain reaction (RT-qPCR) and immunohistochemical staining of cervical carcinoma tissues supported these findings. Enrichment analysis showed that APOBEC3B co-expressed genes were mainly enriched in cell cycle, DNA replication and chromosomal region. Moreover, APOBEC3B expression was significantly associated with T stage, M stage, primary therapy outcome and poor clinical prognosis in cervical cancer. Similarly, APOBEC3B was closely correlated with gene markers of diverse immune cells. APOBEC3B expression was an independent indicator of cervical cancer prognosis, according to univariate Cox and ROC analyses.</p><p><strong>Conclusion: </strong>High APOBEC3B expression is strongly related to a poor prognosis in cervical cancer patients.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 3","pages":"48-56"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076974/pdf/ijcep0016-0048.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9326026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of malignancy and tuberculosis: is it double disease or double hit related to COVID-19? - Experience from a tertiary care center.","authors":"Subhashini Ramamoorthy,&nbsp;Bheemanathi Hanuman Srinivas,&nbsp;Bhawana Ashok Badhe,&nbsp;Sreerekha Jinkala,&nbsp;Rajesh Nachiappa Ganesh","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Coexistent malignancy and tuberculosis (TB) are rarely encountered. Cancer patients are a highly vulnerable subgroup during this Covid crisis. Delayed treatment for malignancy because of COVID-19 pandemic leads to higher chances to get infections.</p><p><strong>Purpose: </strong>The present study aimed to present the clinicopathologic profile of the patients with coexistent carcinoma and TB during the COVID-19 pandemic in a tertiary care center.</p><p><strong>Materials and methods: </strong>This was a retrospective study conducted during the COVID-19 pandemic between April 2020 to May 2021 in the Department of Pathology of our Institute. 11 patients with coexistent malignancy and caseous necrotizing granulomatous inflammation with Langhans giant cells and or acid-fast bacilli (AFB) positivity were included in the study. Cases of ill-defined granulomas coexistent malignancy were excluded. We studied varied clinical and histopathologic features of these cases.</p><p><strong>Results: </strong>Eleven cases were reported with coexistent malignancy and tuberculosis, of which 8 were reported in 2021 and 3 cases were reported in 2020. Adenocarcinoma comprised 9 cases (81.8%) and the remaining 2 were squamous cell carcinoma (18.1%). Out of 11, 10 (90.9%) were new TB cases. Of these, 10 were extrapulmonary TB and one pulmonary TB case with cancer. Regarding chemotherapy, four patients accepted that chemotherapy was delayed because of the COVID-19 crisis.</p><p><strong>Conclusion: </strong>In this covid pandemic, India being the 2^nd most populous country and endemic for TB, there is a higher chance of latent and active TB. The coexistence of two different pathologies is rare, even in a region with a high incidence of TB. Delayed chemotherapy in a pandemic situation leads to an increased incidence of infectious diseases such as TB.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 1","pages":"1-7"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929613/pdf/ijcep0016-0001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9328786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-199a-3p promotes repair of myocardial infarction by targeting NACC2.","authors":"Xue-Zheng Wang,&nbsp;Lei Chen,&nbsp;Hao Sun,&nbsp;Xiao-Qian Li,&nbsp;Hu Wang,&nbsp;Xiao-Peng Zhang,&nbsp;Jiang-Bin Sun,&nbsp;Hai-Yong Wang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Myocardial infarction (MI) has gained widespread interest due to its high death and disability rate worldwide. Some miRNAs are markers of heart disease. Therefore, it is necessary to understand the mechanism for repairing MI injury.</p><p><strong>Methods: </strong>Here, we evaluated the relative expression levels of miR-199a-3p in mouse and human myocardial cell models of injury, and its effect on myocardial cells viability using Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2'-deoxyuridline (EdU) assay, and flow cytometry assay as well as western blot in vitro. Furthermore, we performed bioinformatic online analysis to investigate the role that miR-199a-3p plays in cardiomyocyte injury, measured by dual-luciferase reporter assay.</p><p><strong>Results: </strong>The results showed that miR-199a-3p significantly increased the growth rate of cardiomyocytes after treating them with hydrogen peroxide (H₂O₂). miR-199a-3p also acted as an inhibitor that directly targeted NACC2, resulting in a higher NACC2 expression level in the injury model of cardiomyocytes than normal myocardial cells and thus preventing miR-199a-3p-induced proliferation promotion in model cardiomyocytes.</p><p><strong>Conclusion: </strong>Our results demonstrate that miR-199a-3p may be a prognostic biomarker in myocardial injury.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 3","pages":"57-66"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076973/pdf/ijcep0016-0057.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic utility of C4d immunohistochemistry in membranous nephropathy.","authors":"Bheemanathi Hanuman Srinivas,&nbsp;Norton Stephen,&nbsp;Priyamvada Ps","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Membranous nephropathy (MN), also called membranous glomerulopathy, is one of the leading causes of nephrotic syndrome in adults which is defined by the presence of subepithelial immune complex deposits with a spectrum of changes in the glomerular basement membrane (GBM). It is known that C4d is a byproduct of the classic and lectin pathway. There is deposition of C4d noted in the cases of immune complex-mediated glomerulonephritis involving the classical/lectin pathway including MN. The main objective of this study is to assess the utility C4d as an immunohistochemical (IHC) stain in MN.</p><p><strong>Materials: </strong>A total of 43 cases of MN (primary & secondary) were taken, and 39 cases of minimal change disease (MCD)/focal segmental glomerulosclerosis (FSGS) were used as the control group. All the relevant data were retrieved from the hospital database. C4d immunohistochemistry was performed in the cases as well as the control group.</p><p><strong>Results: </strong>A diffuse continuous staining pattern in the glomeruli was observed in cases of primary MN whereas a discontinuous staining in the glomerulI favors a secondary MN. 26/29 cases of MCD showed positivity in the podocytes. Among the cases of FSGS, 7/10 cases showed positivity in the podocytes with 3 cases showing an associated mesangial blush pattern of staining.</p><p><strong>Conclusion: </strong>Very few studies are available demonstrating the importance of C4d IHC in MN. C4d IHC can be a useful adjunct for immunofluorescence, especially in cases of early MN.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 5","pages":"94-98"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244228/pdf/ijcep0016-0094.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9663292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors associated with lymph node metastasis in patients with small papillary thyroid carcinomas.","authors":"Haoying Sun,&nbsp;Ming Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to analyze risk factors for central lymph node metastasis (CLNM) in patients with small papillary thyroid carcinoma (PTC).</p><p><strong>Methods: </strong>The clinicopathologic data of 375 patients with small PTC admitted to the Affiliated Hospital of Inner Mongolia Medical University from January 2017 to December 2020 were analyzed retrospectively. The patients were divided into two groups, namely, CLNM (n = 177) and non-CLNM (n = 198) groups. Relevant data from the two groups were analyzed using the chi-square test, logistic regression analysis, and the receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>The CLNM rate of the 375 patients with small PTC was 47.2%. The chi-square test revealed that CLNM status was correlated with a patient's gender and age as well as tumor size, number of lesions, and invasion of the thyroid capsule (P < 0.05), but not with BRAF gene mutation, Hashimoto's thyroiditis (HT), or nodular goiter. Multivariate analysis indicated significant differences in gender, maximum tumor diameter, multifocality, and thyroid adventitial infiltration between the two groups (all P < 0.05) but no significant difference between the two groups in regard to HT and nodular goiter. The ROC curve suggested that age ≤ 26.5 years and maximum tumor diameter ≥ 0.75 cm were thresholds for increased risk of CLNM.</p><p><strong>Conclusions: </strong>Lymph node metastasis in the central area of small PTC is associated with multiple factors. Careful examination, analysis, and evaluation of these factors can help in developing accurate individualized treatment strategies.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 5","pages":"86-93"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244229/pdf/ijcep0016-0086.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9965002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of expression level of ZNF471 in gastric cancer.","authors":"Siyuan Li,&nbsp;Diyang Chen,&nbsp;Huamin Zhang,&nbsp;Yong Yang,&nbsp;Jianguo Huai,&nbsp;Linna Huang,&nbsp;Kai Fan,&nbsp;Tongyuan Lin,&nbsp;Baijing Ding","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>As a tumor suppressor gene, zinc finger protein 471 (ZNF471) has an essential role in tumor occurrence and development. Due to promoter hypermethylation, it can be underexpressed or silenced in gastric cancer (GC) cell lines. In this study, we investigated relationships between clinical characteristics and ZNF471 expression levels in tissues of patients with GC.</p><p><strong>Methods: </strong>We used immunohistochemistry (IHC) to detect ZNF471 expression in paraffin tissue specimens, and quantitative real-time PCR (qRT-PCR) and western blot (WB) analysis to measure expression levels of ZNF471 in fresh tissue specimens. We analyzed relationships between ZNF471 expression levels and characteristics, such as tumor size, gender, age, TNM stage, and lymph node metastasis.</p><p><strong>Results: </strong>Immunohistochemistry revealed the expression of ZNF471 protein from paraffin blocks of GC tissues was significantly lower than that of adjacent tissues. Expression levels of ZNF471 mRNA and protein in fresh GC tissues were markedly lower than those in adjacent tissues and in normal gastric mucosal tissues from healthy subjects. ZNF471 expression was significantly correlated with tumor size, lymph node metastasis, and TNM stage (all <i>P</i><0.05). There were no significant associations with gender, age, distant metastasis, or pathologic type. Expression of ZNF471 mRNA and protein was not significantly different between adjacent tissues of patients with GC and normal gastric mucosal tissue from healthy subjects.</p><p><strong>Conclusion: </strong>ZNF471 functions as a tumor suppressor during the pathogenesis of GC. Thus, it is a promising biomarker for diagnosis and therapy of GC.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 8","pages":"199-208"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492033/pdf/ijcep0016-0199.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}